Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | NNMT | P40261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1882869 | 0.92 | GAA (0.50) | LMNAKMT2AHTTRAB9APOLB | |
| SCHEMBL1881365 | 0.82 | KMT2A (0.52) | HPGDLMNAKMT2AHTTRAB9A | |
| SCHEMBL1709292 | 0.74 | HPGD (0.65) | HPGDLMNAKMT2AHTTRAB9A | |
| SCHEMBL15189091 | 0.73 | KMT2A (0.50) | HPGDLMNAKMT2AHTTRAB9A | |
| SCHEMBL4963071 | 0.71 | LMNA (0.56) | HPGDLMNAKMT2AHTTRAB9A | |
| SCHEMBL24306039 | 0.70 | HPGD (0.59) | HPGDLMNAKMT2AHTTRAB9A | |
| SCHEMBL1709361 | 0.70 | RIPK1 (0.71) | HPGDLMNAKMT2AHTTRAB9A | |
| SCHEMBL1274911 | 0.69 | LMNA (0.68) | HPGDLMNAKMT2AHTTRAB9A | |
| SCHEMBL6468546 | 0.68 | RAB9A (0.68) | HPGDLMNAKMT2AHTTRAB9A | |
| SCHEMBL24779944 | 0.67 | HPGD (0.59) | HPGDLMNAKMT2AHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519188-B2 | Compounds which can be used for the treatment of cancers | Marc-Henry Pitty (FR) | 2013-08-27 | — | — | US | disclosed |
| US-8519188-B2 | Compounds which can be used for the treatment of cancers | Marc-Henry Pitty (FR) | 2013-08-27 | — | — | US | disclosed |
| EP-2307017-B1 | COMPOUNDS WHICH CAN BE USED FOR THE TREATMENT OF CANCERS | PITTY MARC HENRY (FR) | 2013-08-14 | — | — | EP | disclosed |
| EP-2307017-B1 | COMPOUNDS WHICH CAN BE USED FOR THE TREATMENT OF CANCERS | PITTY MARC HENRY (FR) | 2013-08-14 | — | — | EP | disclosed |
| US-20110104162-A1 | Compounds which can be used for the Treatment of Cancers | CYTOMICS SYSTEMS (FR) | 2011-05-05 | — | — | US | disclosed |
| US-20110104162-A1 | Compounds which can be used for the Treatment of Cancers | CYTOMICS SYSTEMS (FR) | 2011-05-05 | — | — | US | disclosed |
| WO-2009150248-A1 | COMPOUNDS WHICH CAN BE USED FOR THE TREATMENT OF CANCERS | CYTOMICS SYSTEMS (FR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104162-A1 | Compounds which can be used for the Treatment of Cancers | VHL, CYP11B2, SLC10A1 | HPGD 234/4885NNMT 711/4885LMNA 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.